Metabolomic analysis reveals metabolic disturbance in the cortex and hippocampus of subchronic MK-801 treated rats. 2013

Liya Sun, and Juan Li, and Kejun Zhou, and Ming Zhang, and Jinglei Yang, and Yang Li, and Baohu Ji, and Zhao Zhang, and Hui Zhu, and Lun Yang, and Guang He, and Linghan Gao, and Zhiyun Wei, and Kejian Wang, and Xue Han, and Weiqing Liu, and Liwen Tan, and Yihua Yu, and Lin He, and Chunling Wan
Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, PR China.

BACKGROUND Although a number of proteins and genes relevant to schizophrenia have been identified in recent years, few are known about the exact metabolic pathway involved in this disease. Our previous proteomic study has revealed the energy metabolism abnormality in subchronic MK-801 treated rat, a well-established animal model for schizophrenia. This prompted us to further investigate metabolite levels in the same rat model to better delineate the metabolism dysfunctions and provide insights into the pathology of schizophrenia. METHODS Metabolomics, a high-throughput investigatory strategy developed in recent years, can offer comprehensive metabolite-level insights that complement protein and genetic findings. In this study, we employed a nondestructive metabolomic approach (1H-MAS-NMR) to investigate the metabolic traits in cortex and hippocampus of MK-801 treated rats. Multivariate statistics and ingenuity pathways analyses (IPA) were applied in data processing. The result was further integrated with our previous proteomic findings by IPA analysis to obtain a systematic view on our observations. RESULTS Clear distinctions between the MK-801 treated group and the control group in both cortex and hippocampus were found by OPLS-DA models (with R(2)X = 0.441, Q(2)Y = 0.413 and R(2)X = 0.698, Q(2)Y = 0.677, respectively). The change of a series of metabolites accounted for the separation, such as glutamate, glutamine, citrate and succinate. Most of these metabolites fell in a pathway characterized by down-regulated glutamate synthesis and disturbed Krebs cycle. IPA analysis further confirmed the involvement of energy metabolism abnormality induced by MK-801 treatment. CONCLUSIONS Our metabolomics findings reveal systematic changes in pathways of glutamate metabolism and Krebs cycle in the MK-801 treated rats' cortex and hippocampus, which confirmed and improved our previous proteomic observation and served as a valuable reference to the etiology research of schizophrenia.

UI MeSH Term Description Entries
D008297 Male Males
D009415 Nerve Net A meshlike structure composed of interconnecting nerve cells that are separated at the synaptic junction or joined to one another by cytoplasmic processes. In invertebrates, for example, the nerve net allows nerve impulses to spread over a wide area of the net because synapses can pass information in any direction. Neural Networks (Anatomic),Nerve Nets,Net, Nerve,Nets, Nerve,Network, Neural (Anatomic),Networks, Neural (Anatomic),Neural Network (Anatomic)
D004734 Energy Metabolism The chemical reactions involved in the production and utilization of various forms of energy in cells. Bioenergetics,Energy Expenditure,Bioenergetic,Energy Expenditures,Energy Metabolisms,Expenditure, Energy,Expenditures, Energy,Metabolism, Energy,Metabolisms, Energy
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D006706 Homeostasis The processes whereby the internal environment of an organism tends to remain balanced and stable. Autoregulation
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016194 Receptors, N-Methyl-D-Aspartate A class of ionotropic glutamate receptors characterized by affinity for N-methyl-D-aspartate. NMDA receptors have an allosteric binding site for glycine which must be occupied for the channel to open efficiently and a site within the channel itself to which magnesium ions bind in a voltage-dependent manner. The positive voltage dependence of channel conductance and the high permeability of the conducting channel to calcium ions (as well as to monovalent cations) are important in excitotoxicity and neuronal plasticity. N-Methyl-D-Aspartate Receptor,N-Methyl-D-Aspartate Receptors,NMDA Receptor,NMDA Receptor-Ionophore Complex,NMDA Receptors,Receptors, NMDA,N-Methylaspartate Receptors,Receptors, N-Methylaspartate,N Methyl D Aspartate Receptor,N Methyl D Aspartate Receptors,N Methylaspartate Receptors,NMDA Receptor Ionophore Complex,Receptor, N-Methyl-D-Aspartate,Receptor, NMDA,Receptors, N Methyl D Aspartate,Receptors, N Methylaspartate
D016291 Dizocilpine Maleate A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects. Dizocilpine,MK-801,MK 801,MK801
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats

Related Publications

Liya Sun, and Juan Li, and Kejun Zhou, and Ming Zhang, and Jinglei Yang, and Yang Li, and Baohu Ji, and Zhao Zhang, and Hui Zhu, and Lun Yang, and Guang He, and Linghan Gao, and Zhiyun Wei, and Kejian Wang, and Xue Han, and Weiqing Liu, and Liwen Tan, and Yihua Yu, and Lin He, and Chunling Wan
February 2003, Journal of neuroscience research,
Liya Sun, and Juan Li, and Kejun Zhou, and Ming Zhang, and Jinglei Yang, and Yang Li, and Baohu Ji, and Zhao Zhang, and Hui Zhu, and Lun Yang, and Guang He, and Linghan Gao, and Zhiyun Wei, and Kejian Wang, and Xue Han, and Weiqing Liu, and Liwen Tan, and Yihua Yu, and Lin He, and Chunling Wan
March 2004, Proteomics,
Liya Sun, and Juan Li, and Kejun Zhou, and Ming Zhang, and Jinglei Yang, and Yang Li, and Baohu Ji, and Zhao Zhang, and Hui Zhu, and Lun Yang, and Guang He, and Linghan Gao, and Zhiyun Wei, and Kejian Wang, and Xue Han, and Weiqing Liu, and Liwen Tan, and Yihua Yu, and Lin He, and Chunling Wan
October 1997, Experimental neurology,
Liya Sun, and Juan Li, and Kejun Zhou, and Ming Zhang, and Jinglei Yang, and Yang Li, and Baohu Ji, and Zhao Zhang, and Hui Zhu, and Lun Yang, and Guang He, and Linghan Gao, and Zhiyun Wei, and Kejian Wang, and Xue Han, and Weiqing Liu, and Liwen Tan, and Yihua Yu, and Lin He, and Chunling Wan
December 2013, Behavioural pharmacology,
Liya Sun, and Juan Li, and Kejun Zhou, and Ming Zhang, and Jinglei Yang, and Yang Li, and Baohu Ji, and Zhao Zhang, and Hui Zhu, and Lun Yang, and Guang He, and Linghan Gao, and Zhiyun Wei, and Kejian Wang, and Xue Han, and Weiqing Liu, and Liwen Tan, and Yihua Yu, and Lin He, and Chunling Wan
January 2022, Ultrastructural pathology,
Liya Sun, and Juan Li, and Kejun Zhou, and Ming Zhang, and Jinglei Yang, and Yang Li, and Baohu Ji, and Zhao Zhang, and Hui Zhu, and Lun Yang, and Guang He, and Linghan Gao, and Zhiyun Wei, and Kejian Wang, and Xue Han, and Weiqing Liu, and Liwen Tan, and Yihua Yu, and Lin He, and Chunling Wan
June 2024, Neuropsychopharmacology reports,
Liya Sun, and Juan Li, and Kejun Zhou, and Ming Zhang, and Jinglei Yang, and Yang Li, and Baohu Ji, and Zhao Zhang, and Hui Zhu, and Lun Yang, and Guang He, and Linghan Gao, and Zhiyun Wei, and Kejian Wang, and Xue Han, and Weiqing Liu, and Liwen Tan, and Yihua Yu, and Lin He, and Chunling Wan
April 2023, Behavioural brain research,
Liya Sun, and Juan Li, and Kejun Zhou, and Ming Zhang, and Jinglei Yang, and Yang Li, and Baohu Ji, and Zhao Zhang, and Hui Zhu, and Lun Yang, and Guang He, and Linghan Gao, and Zhiyun Wei, and Kejian Wang, and Xue Han, and Weiqing Liu, and Liwen Tan, and Yihua Yu, and Lin He, and Chunling Wan
August 2023, Nutrition, metabolism, and cardiovascular diseases : NMCD,
Liya Sun, and Juan Li, and Kejun Zhou, and Ming Zhang, and Jinglei Yang, and Yang Li, and Baohu Ji, and Zhao Zhang, and Hui Zhu, and Lun Yang, and Guang He, and Linghan Gao, and Zhiyun Wei, and Kejian Wang, and Xue Han, and Weiqing Liu, and Liwen Tan, and Yihua Yu, and Lin He, and Chunling Wan
February 2009, Pharmacology, biochemistry, and behavior,
Liya Sun, and Juan Li, and Kejun Zhou, and Ming Zhang, and Jinglei Yang, and Yang Li, and Baohu Ji, and Zhao Zhang, and Hui Zhu, and Lun Yang, and Guang He, and Linghan Gao, and Zhiyun Wei, and Kejian Wang, and Xue Han, and Weiqing Liu, and Liwen Tan, and Yihua Yu, and Lin He, and Chunling Wan
July 1993, Behavioural brain research,
Copied contents to your clipboard!